Company Overview and News

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-09-21 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-09-21 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

9
Top Analyst Has 4 Stocks to Buy Now That May Outperform the Rest of 2018

2018-09-21 247wallst
With third-quarter earnings reports right around the corner, and Wall Street starting to focus on the final three months of 2018, one thing is for sure. The markets have hit all-time highs, and despite a plethora of reasons to be concerned, volatility is once again extremely low. As we are in a late cycle market, it makes sense to look for value and for some safety, and the analysts at Oppenheimer might be on to the sector that has both.
T TMUSP TMUS WIFI TWX ZAYO TWC

14
Interactive Brokers - U.S. Telecom Stocks Surge As 5G Ambitions Intensify

2018-09-20 seekingalpha
U.S.-based telecom sector stocks have been soaring amid progress towards advancing 5G (next generation) technology and despite global competition.
XLNX K3ED CHLKF CHJHF TMUS CMCSA CHA 0941 0762 CHL CHUFF ADI VZ 0728 CCI CHU QCOM

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-09-20 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-09-20 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

49
5 Stocks to Buy Amid a Prolonged Trade War Slump

2018-09-19 investorplace
Yesterday, President Donald Trump announced a new round of tariffs on Chinese goods — $200 billion to be exact. In response, China issued a $60 billion levy on U.S. goods. In an increasingly global economy, prospects for a trade war with China tend to foster nervousness among investors.
DLTR X S T TMUS DG VZ SAVE STZ CGC LUV

16
Implied Volatility Surging for T-Mobile (TMUS) Stock Options

2018-09-18 zacks
Investors in T-Mobile US, Inc. (TMUS - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $80.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
INO TMUSP TMUS MDPEB DXC.WI MDP DXC

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-09-17 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-09-17 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

58
5 5G Stocks to Buy That Will Stream Higher Profits for Investors

2018-09-14 investorplace - 4
As telcos launch the first of the 5G networks, 5G stocks will become a focus. The technology will change wireless. How much speed it will add has become a point of controversy. Estimates from a few years ago predicted the improvement at 1,000 times 4G.
BRK.A S T TMUS AAPL CSCO NOK INTC

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-09-13 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-09-13 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

41
Telecom Stock Roundup: Verizon 5G Internet Service, Ericsson-T-Mobile 5G Deal & More

2018-09-13 zacks
In the past five trading days, the uptrend in telecom stocks continued driven by healthy job growth data exhibiting signs of a strengthening economy. The stocks were also fueled by optimism from a U.S. proposal to initiate talks with China in the near future to iron out the trade-related differences between the two countries. Per the U.S. Labor Department report, about 201,000 new jobs were created in August, marking the 95th straight month of employment gains in the country.
FNSR ARRS S TMUSP TMUS JNPR VZ VZA

84
Bull And Bear Markets Within S&P 500 - Cramer's Mad Money (9/12/18)

2018-09-13 seekingalpha - 1
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, September 12.
NEWR LRCX FB PG NOW PSX AMD TLRY ADBE HUBS EL OKTA AMAT SSTI SNAP TEAM SPLK TMUSP DATA TMUS KMB LOGI COUP BP T MU GOOGL KHC VZ HEAR FIVE FANG

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 872590104